CNTX - NASDAQ
Context Therapeutics Inc.
$2.03
-16%Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live Snapshotcntx
Cash at End of Period
Last Annual Value
66.00M
3-Year CAGR
23%
5-Year CAGR
187%
10-Year CAGR
76%
Context Therapeutics Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Context Therapeutics Inc. NASDAQ:CNTX | 66.00M | 65.9% | 5.8% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 45.95M | 71.8% | -9.9% | 28.0% | |
 Shattuck Labs, Inc. NASDAQ:STTK | 54.19M | -24.4% | -10.1% | N/A | |
 Agenus Inc. NASDAQ:AGEN | 44.07M | -17.9% | -31.6% | -4.7% | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 37.00M | 7.3% | -7.5% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 3.62M | -0.4% | -8.2% | -5.8% | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 13.39M | -13.1% | -40.9% | N/A | |
 Seer, Inc. NASDAQ:SEER | 47.81M | 13.1% | -27.2% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 157.44M | 4.4% | -1.1% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 67.13M | 59.2% | -8.2% | 65.8% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 14.08M | -9.9% | 4.2% | 9.4% |
Context Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your CNTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.